TSBX - Rasio utang marang kapitalisasi buku Turnstone Biologics Corp

The historical trend of the debt-to-book capitalization ratio, where the latest reading is 0.03, is based on the delegation of clinical trials to external CRO centers. Turnstone Biologics (TSBX) seeks pricing power in oncology through unique TIL lymphocyte selection. A team of viral platform experts is retained on staff due to scientific freedom and ownership of company shares.

TSBX Turnstone Biologics Corp: Rasio utang marang kapitalisasi buku ing interval 21.02.2024 - 24.08.2025

Selecting stocks with a high margin of fundamental strength begins with an analysis of the debt load. The `dvsbcap_co` ratio measures the ability of equity to cover all liabilities, determining financial stability or the degree of leverage. For Turnstone Biologics (TSBX), this balance is critical when financing the development of TIL therapy against solid tumors. An optimal resource ratio ensures the advancement of innovation without the risk of bankruptcy. This price action reflects the capital structure trend: debt to book capitalization.

Pesaing Turnstone Biologics

ImmunityBio, Inc. - Utang-utang marang kapitalisasi buku|immunocore.com - Utang marang nilai buku|JANX (Janux Therapeutics, Inc.) - Rasio utang marang kapitalisasi buku|RCUS: Utang-utang marang nilai buku|Zymeworks Corp (ZYME) - Rasio utang marang kapitalisasi buku|TNGX (Tango Therapeutics Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku IOVA (Iovance Biotherapeutics)|Utang-utang marang nilai buku immatics.com|XNCR: Utang-utang marang kapitalisasi buku|Utang marang aset resik Compass Therapeutics Inc CMPX|REPL: Utang marang nilai buku|LYEL - Utang-utang marang nilai buku|Utang marang nilai buku Innate Pharma S.A. (IPHA)|PYXS - Rasio utang marang aset resik|cgen.com - Utang-utang marang kapitalisasi buku|IOBT (IO Biotech Inc) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku STRO|Utang marang nilai buku INKT|Rasio utang marang kapitalisasi buku HOWL (Werewolf Therapeutics)|Utang marang nilai buku immixbio.com IMMX|Utang marang nilai buku ALXO (ALX Oncology Holdings)|cuebiopharma.com - Utang-utang marang kapitalisasi buku|PDS Biotechnology Corp (PDSB) - Rasio utang marang kapitalisasi buku|SONN: Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku MAIA|Utang-utang marang nilai buku liminatuspharma.com|LAVA Therapeutics NV - Utang marang nilai buku|Utang marang aset resik NextCure Inc (NXTC)|Utang marang nilai buku Leap Therapeutics, Inc.|Utang marang modal buku intensitytherapeutics.com (INTS)|Utang-utang marang kapitalisasi buku Sensei Biotherapeutics, Inc.|Rasio utang marang aset resik therivabio.com TOVX|GRTS (Gritstone Bio) - Utang-utang marang kapitalisasi buku|KA: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku NexImmune Corp NEXI|Vaccinex Inc (VCNX) - Rasio utang marang aset resik|HARP (Harpoon Therapeutics) - Utang-utang marang kapitalisasi buku